SCHEMBL3473121

SCHEMBL3473121

O=C(O)c1ccc(-c2ccc(-c3cc(C(F)(F)F)nn3-c3ccccc3Cl)s2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 6/20 0.68
NR1H2 P55055 6/20 0.68
NR1H3 Q13133 6/20 0.68
NR3C2 P08235 1/20 0.46
PTGS2 P35354 2/20 0.46
PTGS1 P23219 2/20 0.41
RORC P51449 2/20 0.41
PPARG P37231 1/20 0.41
HDAC1 Q13547 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
MAPT P10636 2/20 0.40
TP53 P04637 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
ALDH1A1 P00352 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
MARS1 P56192 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3473215 0.93 RXRA (0.69) RXRANR1H2NR1H3NR3C2PTGS2
SCHEMBL3473137 0.89 RXRA (0.71) RXRANR1H2NR1H3RORCPPARG
SCHEMBL3472956 0.88 RXRA (0.62) RXRANR1H2NR1H3NR3C2PTGS2
SCHEMBL3471768 0.87 RXRA (0.65) RXRANR1H2NR1H3NR3C2PTGS2
SCHEMBL3472699 0.86 RXRA (0.66) RXRANR1H2NR1H3NR3C2PTGS2
SCHEMBL3474696 0.85 RXRA (0.62) RXRANR1H2NR1H3NR3C2PTGS2
SCHEMBL3472456 0.85 RXRA (0.62) RXRANR1H2NR1H3NR3C2PTGS2
SCHEMBL3474697 0.85 RXRA (0.62) RXRANR1H2NR1H3NR3C2PTGS2
SCHEMBL3471620 0.84 RXRA (0.66) RXRANR1H2NR1H3NR3C2PTGS2
SCHEMBL3473887 0.84 RXRA (0.74) RXRANR1H2NR1H3PTGS2PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US claimed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331295-A1 MODULATORS OF LXR NR1H2, NR1H3, NR1H4 RXRA 18/4885NR1H2 1/4885NR1H3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.